 The German biotech company CureVac BV NASDAQ: CVAC announced on Wednesday after hours the final results of its late-stage COVID-19 vaccine trial showing 48 effectiveness at preventing the disease, which is slightly higher than seen in a preliminary readout. But it lagged the efficacy rates of more than 90 shown by Pfizer Inc NYSE: PFE - BioNTech SE NASDAQ: BNTX and Moderna Incs NASDAQ: MRNA mRNA shots. 